EJHaem最新文献

{"title":"Correction to “Catastrophic Venous and Arterial Thrombosis in a Young Female With Cervical Cancer”","authors":"","doi":"10.1002/jha2.70149","DOIUrl":"https://doi.org/10.1002/jha2.70149","url":null,"abstract":"<p>J. Burgess, F. Hendry, C. Bagot, and B. Doherty, “Catastrophic Venous and Arterial Thrombosis in a Young Female With Cervical Cancer,” <i>eJHaem</i> 5, no. 4 (2024): 879–880, https://doi.org/10.1002/jha2.973.</p><p>Email address for Jordan Burgess has been removed from original article due to phishing activity.</p><p>We apologise for this error.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class–Exposed and BCMA-Exposed Multiple Myeloma Within the United States","authors":"Hira S. Mian,&nbsp;Jennifer S. Harper,&nbsp;Hoa H. Le,&nbsp;Alex Z. Fu,&nbsp;Saurabh Patel,&nbsp;Xinke Zhang,&nbsp;Rafael Fonseca","doi":"10.1002/jha2.70145","DOIUrl":"10.1002/jha2.70145","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A novel therapy for heavily pretreated triple-class–exposed multiple myeloma (TCE MM) is B-cell maturation antigen (BCMA)-targeted immunotherapy. While the number of TCE+BCMA-exposed patients is growing, real-world data for this group are limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We present real-world data from patients with TCE+BCMA-exposed MM who initiated a subsequent line of therapy (LOT) using a US-based claims database, Komodo's Healthcare Map.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 656 TCE+BCMA-exposed patients; mean age was 66.5 years. Time from MM diagnosis to index was 5.4 years; mean number of prior LOTs was 5.9. The most prevalent prior therapy received within each drug class was daratumumab (98.5%), pomalidomide (86.0%), carfilzomib (85.8%) and belantamab mafodotin (74.5%). A total of 137 different subsequent treatment regimens were observed following TCE+BCMA exposure; the most common regimen was teclistamab (10.4%). The top three targeted agents within the subsequent regimen were carfilzomib (20.2%), pomalidomide (20.1%) and bortezomib (16.6%). Among this TCE+BCMA-exposed population who received subsequent treatment, the median time to next treatment or death was 6.8 (95% CI, 6.1–7.5) months; time to treatment discontinuation or death was 3.5 (95% CI, 3.2–3.7) months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This first real-world analysis of patients with heavily pretreated TCE+BCMA-exposed MM shows poor clinical outcomes, frequent therapy retreatment and no standard-of-care, highlighting the need for novel treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trial Registration</h3>\u0000 \u0000 <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “First Report of MPL c.23T>G (p.M8R) Variant in Congenital Amegakaryocytic Thrombocytopenia: A Case Report”","authors":"","doi":"10.1002/jha2.70148","DOIUrl":"https://doi.org/10.1002/jha2.70148","url":null,"abstract":"<p>A. Latifi and S. Yousefian, “First Report of MPL c.23T&gt;G (p.M8R) Variant in Congenital Amegakaryocytic Thrombocytopenia: A Case Report,” <i>eJHaem</i> 6, no. 5 (2025): e70136, https://doi.org/10.1002/jha2.70136.</p><p>The authorship statement “Dr. Atbin Latifi shared the first authorship and Dr. Sina Yousefian second authorship.” was incorrect.</p><p>This should have read: “Dr. Atbin Latifi and Dr. Sina Yousefian contributed equally and share first authorship.”</p><p>We apologize for this error.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Hospital-at-Home Services for Injectable Chemotherapy for Patients With Multiple Myeloma in France in 2019 and 2020: A Real-World Nationwide Study Based on the French Hospital Discharge Database","authors":"Laure Vincent,&nbsp;Anne-Sophie Jannot,&nbsp;Hakima Mechiche,&nbsp;Ulysse Rodts,&nbsp;Gaëlle Désaméricq","doi":"10.1002/jha2.70144","DOIUrl":"https://doi.org/10.1002/jha2.70144","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Some injectable medicines introduced recently allow patients with multiple myeloma (MM) to receive their chemotherapy at home. This study aimed at describing adult patients with MM receiving injectable chemotherapy via hospital-at-home (HAH) services and outpatient hospital units (OHUs) in metropolitan France in 2019 and 2020, analyzing the factors influencing HAH use, and evaluating the geographic variations and the evolution over time of HAH use by these patients during the study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Real-world data from the French Hospital Discharge Database (PMSI) were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 2169/9278 patients (23.4%) received at least one HAH chemotherapy injection. These patients were diagnosed more recently (mean ± standard deviation = 25.1 ± 19.6 vs. 31.6 ± 21.8 months), and lived in larger and wealthier cities (59,000 vs. 41,000 inhabitants; €23,300 ± €5300 vs. €21,700 ± €4100) and closer to their follow-up hospital (18.7 ± 18.4 vs. 31.3 ± 31.2 km) than patients exclusively treated in OHUs (<i>p</i> &lt; 0.001). Receiving bortezomib and carfilzomib, and the first chemotherapy dose in 2020, were the most significant factors associated with HAH use (odds ratio [95% confidence interval]: 6.12 [5.40–6.96], 2.01 [1.69-2.39], and 1.81 [1.57–2.09], respectively, <i>p</i> &lt; 0.001). HAH use increased between 2019 and 2020 (patients, +23%; administrative departments, +25%), likely related to the COVID-19 pandemic. However, HAH use remained limited overall and exhibited inter-regional variability. Infection-related hospitalizations remained stable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Receiving chemotherapy injections at home is feasible and safe, but further development and equitable access are essential to enhance patients’ quality of life and reduce costs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT-2 Inhibitors Are Potent to Suppress Aggressive Transformation From Indolent Type of Adult T-Cell Leukemia/Lymphoma: Unique Insight Into Therapeutics for Diabetes-Related Hematological Malignancy","authors":"Kazuho Morichika,&nbsp;Keita Tamaki,&nbsp;Takuya Fukushima,&nbsp;Hiroaki Masuzaki","doi":"10.1002/jha2.70109","DOIUrl":"https://doi.org/10.1002/jha2.70109","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>We previously reported that sodium-glucose co-transporter 2 (SGLT-2) was ectopically overexpressed in adult T-cell leukemia (ATL) cells notably in aggressive type but in indolent type, and widely-used anti-diabetic SGLT-2 inhibitors (SGLT-2i) considerably attenuated proliferation of leukemic cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed retrospective analyses for 10 years to see whether SGLT-2i would prevent aggressive transformation in patients with indolent type ATL accompanied by diabetes. Nucleosome occupancy in the promotor region of the <i>SGLT-2</i> gene was also assessed to explore the possible involvement of epigenetic modification in such an ectopic overexpression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In patients of indolent ATL with diabetes, the cumulative progression rate in the non-SGLT-2i-treated group was 71%, while no patients developed aggressive transformation in the SGLT-2i treated group. ATL cells showed an apparent trend to decrease nucleosome occupancy in the promotor region of the <i>SGLT-2</i> gene.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data suggest that SGLT-2i is advantageous for preventing aggravative transformation in indolent ATL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Authors confirmed that clinical trial registration was not requested for the present study and this manuscript.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus","authors":"Charlotte Bradbury,&nbsp;Jecko Thachil,&nbsp;Matthew McWilliams,&nbsp;Will A. Lester","doi":"10.1002/jha2.70134","DOIUrl":"https://doi.org/10.1002/jha2.70134","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Immune thrombocytopenia (ITP) is characterised by a low platelet count and increased risk of bleeding. Recent research has also proposed that having ITP increases thrombosis risk. Moreover, certain ITP treatments have been associated with an increased risk of thrombosis. This Delphi study aims to assess haematologist opinion regarding aspects of optimise thrombotic risk management in primary ITP in the UK.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The methodology employed a modified Delphi process with two rounds of evaluation from a panel of experts. A literature review on the topic of primary ITP generated input to a steering group of three experts from the UK attended a virtual meeting in May 2024. During this meeting, and guided by an independent facilitator, the group identified five main domains. From these, 42 statements were agreed and developed into an online survey for testing with a wider panel of peers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 33 statements achieved consensus agreement, and one statement did not achieve consensus. Eight scenario statements were included to identify preferable treatment options among healthcare professionals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Based on the agreement levels achieved, the steering group formulated a set of recommendations to optimise the management of thrombotic risk in patients with primary ITP in the UK.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70134","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of an Electronic Patient Reported Outcome Measures (e-PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With Lymphoma: A Multicenter Prospective Study","authors":"Raúl Córdoba,&nbsp;Marta del Olmo Rodríguez,&nbsp;Sergio Ramos,&nbsp;Alberto López García,&nbsp;Daniel Morillo,&nbsp;Maria-Angeles Pérez-Sáenz,&nbsp;Carolina Miranda,&nbsp;Rafael Martos,&nbsp;Laura Beltrán,&nbsp;Eva Castillo,&nbsp;Antonio Herrero,&nbsp;Alvaro Gómez-Meana,&nbsp;Bernadette Pfang,&nbsp;Jorge Short Apellaniz,&nbsp;Javier Arcos-Campillo","doi":"10.1002/jha2.70129","DOIUrl":"https://doi.org/10.1002/jha2.70129","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Healthcare is shifting from a disease-centered to patient-centered approach, and aspects of health such as quality of life (QoL) are becoming increasingly relevant. “E-Res Salud” for hematological malignancies is a value-based healthcare program aiming to improve patient experience and outcomes. The program collects e-PROMs via automatically deployed, validated questionnaires over a mobile application.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A multicenter prospective observational cohort study including 243 patients with Hodgkin and non-Hodgkin lymphoma receiving outpatient intravenous immunochemotherapy at four teaching hospitals in Madrid, Spain, of whom 121 participated in the “E-Res Salud” program.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that adverse event reporting differs significantly between patients and healthcare professionals. Participants showed significantly lower rates of emergency department visits (37.2% vs. 56.6%; <i>p</i> &lt; 0.01) and unplanned hospital admissions (21.5% vs. 32.8%; <i>p</i> &lt; 0.05), as well as significantly higher rates of treatment completion and overall survival (88.4% vs. 79.5% after 18 months of follow-up; stratified hazard ratio, 2.30; 95% CI 1.25–4.22; <i>p</i> = 0.007).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>An e-PROMS program for patients with lymphoma is associated with lower use of healthcare and improved clinical outcomes. Patients and hematologists report adverse events differently, demonstrating the importance of patient-reported outcome measurement to improve symptom management in clinical practice.</p>\u0000 \u0000 <p><b>Trial Registration</b>: The authors have confirmed clinical trial registration is not needed for this submission</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Prevalence of Psychological Symptoms, Sexual Dysfunction, and Prolonged Medical Leave Two Years After Acute Leukemia Diagnosis—Patient Reported Outcome in Sweden","authors":"Emma Bergfelt Lennmyr,&nbsp;Anna Lübking,&nbsp;Marie Abrahamsson,&nbsp;Gunnar Juliusson,&nbsp;Martin Höglund,&nbsp;Heléne Hallböök","doi":"10.1002/jha2.70142","DOIUrl":"https://doi.org/10.1002/jha2.70142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>With the purpose of identifying unmet needs of patients with acute leukemia, survivors were identified from the Swedish National Acute Leukemia registries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>At six months and at two years from diagnosis, patients were requested by mail to report outcome with focus on depression, sick leave, and sexual dysfunction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 910 patients alive at 6 months, 474 (52%) participated, and of 331 alive at two years, 250 (76%) participated. At two years, the majority ≤65 years, 52%, had returned to work &gt;30 h/week, and 40% were still on medical leave. Economic hardship was common, especially in the latter group. Impaired sexual function, impact on sexual desire, as well as anxiety about infections, were frequently reported. Depression with a PHQ-8 score ≥10 was more prevalent in patients ≤65 years than in older patients. In younger patients, a PHQ-8 score ≥10 was associated with sexual dysfunction, economic hardship, single living, and anxiety of infections, whereas in patients &gt;65 years, single living and economic hardship remained significant. No impact of the Covid-19 pandemic on depression was found.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The use of depression screening instruments and awareness of sexual dysfunction could be of importance in the routine care of acute leukemia patients two years after diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T-Cell Therapy","authors":"Daisuke Ikeda,&nbsp;Tomohiro Nawada,&nbsp;Takumi Kondo,&nbsp;Takayuki Shinohara,&nbsp;Tomohiro Nagano,&nbsp;Saya Kubota,&nbsp;Ryuichiro Hiyama,&nbsp;Masaya Ueno,&nbsp;Hiroki Kobayashi,&nbsp;Keisuke Seike,&nbsp;Hideaki Fujiwara,&nbsp;Noboru Asada,&nbsp;Daisuke Ennishi,&nbsp;Keiko Fujii,&nbsp;Nobuharu Fujii,&nbsp;Masanori Makita,&nbsp;Yoshinobu Maeda","doi":"10.1002/jha2.70138","DOIUrl":"https://doi.org/10.1002/jha2.70138","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Invasive fungal infection (IFI) after chimeric antigen receptor (CAR) T-cell therapy is less common than bacterial and viral infections, but can be fatal once it develops. As most cases occur within 30 days after CAR T-cell infusion, late-onset IFI—particularly mould infection—appears to be under-recognised.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>We report an illustrative case of pituitary aspergillosis developing as late as one year after CD19 CAR T-cell therapy, highlighting a persistent risk in certain patients with delayed immune reconstitution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case underscores the need for continued vigilance and individualised antifungal strategies to prevent IFI beyond the early post-infusion period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70138","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipocytes Impair Mitoxantrone Cytotoxicity Against Acute Lymphoblastic Leukemia","authors":"Michael Cohen,&nbsp;Etan Orgel,&nbsp;Jessica Nevarez-Mejia,&nbsp;Ting Chen,&nbsp;Michael Neely,&nbsp;Stan Louie,&nbsp;Steven D. Mittelman","doi":"10.1002/jha2.70140","DOIUrl":"https://doi.org/10.1002/jha2.70140","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Obesity contributes to poorer clinical outcomes in patients with acute lymphoblastic leukemia. We have shown that adipocytes cause anthracycline resistance by absorbing and metabolizing them into less-active alcohol metabolites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We hypothesized that mitoxantrone, which has a similar cytotoxic mechanism to anthracyclines but is metabolized through different pathways, might overcome this adipocyte-mediated chemoresistance. We treated human BV173 acute lymphoblastic leukemia cells with daunorubicin and mitoxantrone that had been incubated with or without 3T3-L1 adipocytes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Contrary to our hypothesis, adipocytes induced similar chemoresistance to both drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Mitoxantrone is unlikely to be an attractive alternative to overcome adipocyte-mediated anthracycline resistance in patients with obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144918626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}